Abstract
The polymerase chain reaction (PCR), using three primer pairs in the pol, tax, and env regions of the HTLV-I genome, was unable to detect HTLV-I in the blood samples of 54 caucasian subjects with multiple sclerosis who were seronegative for HTLV-I/11. Seventeen HTLV-I/II seropositive (by ELISA and Western blot) subjects used as positive controls were positive with the three primer pairs. The PCR was negative in 47 healthy HTLV-I/II seronegative (by ELISA) subjects at low risk of HTLV-I infection used as negative controls.
These results suggest that there is no association between the occurrence of HTLV-I sequences and the development of multiple sclerosis.
The serological association between human T-lymphotropic virus type I (HTLV-I) infection and a chronic neurological disease such as the tropical spastic paraparesis prompted a search for this infection in other chronic neurological disorders such as multiple sclerosis (MS). The presence of specific antibodies'2 and of HTLV-I sequences determined by in situ hybridisation' in patients with MS has been disputed.'3 Recently, Reddy' and Greenberg, 6 using gene amplification by the polymerase chain reaction (PCR), showed HTLV-I DNA sequences' or related retrovirus' in the peripheral blood mononuclear cells of patients with MS who were seronegative for HTLV-I.
As these results have not been confirmed by others, however,78 Reddy suggested that these discrepancies could have been due to the fact that only a subgroup of such cases could harbour HTLV-I sequences. 5 Doubts therefore persist as to the possible relation between HTLV-I infection and MS. We decided to study a large number of French patients with MS to see if HTLV-I sequences could be detected using a PCR assay, to check if epidemiological differences could explain the discrepancies in previously published assays.
Methods
Fifty four caucasian adults with MS, as defined by Poser et al9, were studied. Mean age at onset of disease was 29-4 years; mean age at the time of the study was 42-2 years; 17 were male. All were seronegative by ELISA DNA was prepared from 5 ml of fresh or frozen peripheral blood. Red cells were lysed by a hypotonic buffer (TRIS-HCG 10 mmol/l, pH = 8 6; magnesium chloride 10 mmol/l; sodium chloride 10 mmol/l). The resulting pellet was washed with the same buffer. DNA was extracted after treatment of the cells in lysis buffer (TRIS-HCI 10 mmol/l, pH = 8-6; EDTA 10 mmol/l, pH = 8; sodium chloride 10 mmol/l; sodium dodecyl sulphate 0 5%; proteinase K 100 ,g/ml) at 42°C overnight. After phenol and chloroform isoamyl alcohol (1 in 24) treatment the DNA was precipitated with ethanol and resuspended in a solution of TRIS-HCI (10 mmol/l, pH = 7 5) and EDTA (1 mmol/l).
PRIMERS AND PROBES
The primers used for PCR amplification and the probes used to detect amplified sequences were derived from the pol, tax, and env regions of HTLV-I sequences: (i) The two pol primers were SK54 and SK55'0 and would be expected to amplify the region between nucleotides (nt) 3365 to 3483 of the sequence described by Seiki." The oligonucleotide probe was SK56, which spans the region between nt 3426 and 3460. (ii) The two env primers have been previously described5 and would be expected to amplify the region between nt 5684 to 6151 of the HTLV-I sequence. The oligonucleotide probe was SG 228,6 which spans the region between nt 5841 and 5880. (iii) The two tax primers were SK43 and SK449 and would be expected to amplify the region between nt 7358 to 7516 of the HTLV-I sequence. The oligonucleotide probe was SK45,9 which spans the region between nt 7447 and 7486 of HTLV-I sequence. PCR 
Results
Patients with MS did not have evidence of HTLV-I sequences with the three primer pairs used. The 17 HTLV-I/II seropositive subjects were all positive for HTLV-I with primer pairs in pol, tax, and env regions. The polymerase chain reaction assay was negative with the same primer pairs in the 47 healthy HTLV-I/II seronegative subjects who acted as negative controls.
Discussion
In the controls amplification was specific for HTLV-I sequences and no amplification of non-specific sequences occurred. Our results in patients with MS conflict with those of Reddy5 and Greenberg,6 and confirm those of Bangham7 and Richardson.8 These discrepancies are difficult to explain. As some cases of tropical spastic paraparesis for which the association with HTLV-I infection has been confirmed can clinically resemble multiple sclerosis, HTLV-I positive MS might have been tropical spastic paraparesis. Furthermore, the exquisite sensitivity of the PCR assay is such that DNA contamination from the laboratory can lead to false positive results. In Reddy's study5 one of the 20 negative controls showed detectable HTLV-I sequences.
Our data strongly suggest that an association between the occurrence of HTLV-I sequences and the development of multiple sclerosis is unlikely. Nothing suggests that this retrovirus may be responsible for MS. We conclude that the discrepancies of results suggest that a quality control for laboratories using the PCR in HTLV-I is indispensable.
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